DNAprint Genomics (DNAG)

[frogdreaming]

Blue, Good Call.

In the interest of fairness, I will agree to 'temporarily' remove the Beth Israel deal from that list. I agree that it is premature to include it at this time.

As to finishing what they start, it is not considered finished if it is still in limbo (patents) so the continued refinement of things, while necessary, is still not 'finished'.

Retinome is the specific exception to the trend. It's value has yet to be determined.

I apologize for being unclear and making general statements when I should have obviously been specific, but what I was refering to as unfinished, were the specific topics mentioned previously. GMED deal, Orchid agreement, Malaysian Grant, Asian Collaboration and Biofrontera deal. These efforts have been announced, touted, expanded, speculated upon, and then faded from sight, all without anyone objecting to a fairly obvious trend.

regards,
frog